Kodiak Sciences says Phase 3 DAYBREAK study met primary endpoints for Zenkuda and tabirafusp-ted in wet AMD

Kodiak Sciences said its Phase 3 DAYBREAK study met primary endpoints, with Zenkuda (tarcocimab tedromer) and tabirafusp-ted (KSI-501) showing non-inferiority to aflibercept in vision gains for wet age-related macular degeneration at year one.

Detected & updated continuously · Source: Nebula